Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-02-12

Clinical Trial Update: Trametinib With GSK2141795 in BRAF Wild-type Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating trametinib with GSK2141795 in BRAF wild-type melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GSK2141795 (GSK2141795)
  • Trametinib (trametinib)

Snippet

Sponsor: Adil Daud | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2020-02-12